One, Two, Three-Peat: Mary Kay Inc. Named #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World for Three Years in a Row
Good things come in threes: iconic beauty brand and global entrepreneurship company Mary Kay Inc. has again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International for the third consecutive year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623000452/en/
Ryan Rogers, Chief Executive Officer of Mary Kay states: "Being named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International three years in a row marks a grand slam achievement for Mary Kay. This repeated milestone reflects years of R&D and marketing efforts to create skin and beauty solutions that meet consumer needs and are loved the world-over. Above all, it demonstrates the transformative power of our Independent Beauty Consultants who are driving this success globally." (Photo Courtesy: Mary Kay Inc.)
Euromonitor International is the foremost provider of global business intelligence, market analysis, and consumer insights with over 50 years of conducting market research across more than 100 countries.
"Being named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International three years in a row marks a grand slam achievement for Mary Kay,” said Ryan Rogers, Chief Executive Officer of Mary Kay. “This repeated milestone reflects years of R&D and marketing efforts to create skin and beauty solutions that meet consumer needs and are loved the world-over. Above all, it demonstrates the transformative power of our Independent Beauty Consultants who are driving this success globally."
In addition to the global recognition, Mary Kay has been named:
- #1 Brand of Facial Make-Up in Latin America,*
- #1 Brand of Lip Products in Latin America,*
- #1 Brand of Color Cosmetics in Mexico,*
- #1 Brand of Skincare and Color Cosmetics in Mexico.*
Sarah Boumphrey, Global Research Director at Euromonitor International, stated, “Our awards reflect the highest standard of excellence in the industries we track, and beauty and direct selling are no exception. Honorees are recognized through a rigorous, data-driven evaluation process that draws on independent research, global market analysis, and deep category expertise. Euromonitor is proud to collaborate with leading companies, like Mary Kay, and this accomplishment signifies their commitment to performance and quality in a highly competitive landscape."
With presence in over 40 markets and millions of Independent Beauty Consultants around the world, Mary Kay continues to set the standard for beauty that empowers and delivers. Several fan-favorite products contribute to Mary Kay’s #1 status, including the iconic TimeWise® skincare line, the dermatologist validated Clinical Solutions® skincare line, the Mary Kay® Oil-Free Eye Makeup Remover beloved by influencers and celebrities, the Mary Kay® Ultimate Mascara™, the Mary Kay Unlimited® Lip Gloss, and the Mary Kay® Waterproof Eyeliner, to name a few.
In 2024 alone, Mary Kay garnered 65 beauty awards around the world. In addition to the Euromonitor International #1 recognition, Mary Kay recently ranked #11 in the Women’s Wear Daily Beauty Inc.’s 2024 Top 100 Beauty Companies.
Mary Kay products are sold by best-in-class Independent Beauty Consultants who provide personalized service to customers in person and online at www.MaryKay.com, and on social and digital media channels.
The Euromonitor award reinforces Mary Kay as one of the world’s best loved brands with a business model and corporate mission focused on empowering women, transforming lives, and helping to protect our natural resources.
Did You Know:
- One Mary Kay® Oil-Free Eye Makeup Remover is sold every 5 minutes around the globe.2
- Nearly 1,500 patents globally are held by Mary Kay for products, technologies, and packaging designs in its global portfolio.3
- Mary Kay’s state-of-the-art Richard R. Rogers (R3) global Manufacturing/R&D Center located in Lewisville, Texas, has a production capacity of up to 1.1 million products per day.
- 62% of Mary Kay’s global R&D teams are women.4
- 81% of Mary Kay’s Global Marketing team & Creative Studio are women.5
- 30% of sales force members who started their Mary Kay business in the past year are under the age of 35.6
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X.
| _____________________________ |
1 “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data” |
* “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data” |
2 Source: Mary Kay Inc., data as of December 2024, for the past 12 months, based on units sold. |
3 Source: Mary Kay Inc., as of 2025. |
4 Source: Women Representation and Leadership at Mary Kay (May 2025). |
5 Source: Women Representation and Leadership at Mary Kay (May 2025). |
6 Source: Mary Kay Inc., 2024 U.S. data. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250623000452/en/
Contacts
Mary Kay Inc. Corporate Communications
marykay.com/newsroom -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fmarykay.com%2Fn
ewsroom&esheet=54280234&newsitemid=20250623000452&lan=en-US&anchor=marykay.com%2
Fnewsroom&index=11&md5=43a0edd3b93dbbac9341674184f29486
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Grid Dynamics Announces AI-Powered Engagement Model Enabling Accelerated Business Transformation for Fortune 1000 Enterprises23.6.2025 16:15:00 EEST | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics)—a prominent technology consulting and digital services provider specializing in AI, platform and product engineering, and digital engagement services—today announced the launch of an innovative AI-powered engagement model for its software engineering services. This new model is specifically engineered to deliver the next level of agility, quality, and accelerated time-to-market for Fortune 1000 enterprises. Grid Dynamics' innovative approach expands its engagement offerings beyond traditional Fixed Price, Time and Materials, and Capacity-based engagements. Key features include: Prompt-driven incremental output: Delivering value through iterative, prompt-guided development. Credit-based service consumption: Pricing aligned with desired outputs rather than effort—offering cost efficiency. AI-benchmarked code quality: Continuous evaluation against industry and client standards—ensuring code quality. Centralized client portal: A s
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges23.6.2025 15:05:00 EEST | Press release
As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623205345/en/ LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech’s analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highli
Sagemcom’s Net Zero Trajectory Approved by SBTi: Target Set for 204023.6.2025 15:00:00 EEST | Press release
Sagemcom Group has today reached a critical milestone in its climate strategy: its Net Zero carbon target for 2040—encompassing all activities and sites within the Group’s consolidated scope—has been officially validated by the Science Based Targets initiative (SBTi). This international endorsement attests to the scientific rigor of Sagemcom’s decarbonization strategy, aligned with the Paris Agreement’s ambition to limit global warming to 1.5°C. It strengthens the Group’s comprehensive climate roadmap, which is built on a significant reduction of greenhouse gas emissions across all scopes: By 2030: A 47% absolute reduction in Scope 1 and Scope 2 emissions (direct emissions and purchased energy), 100% renewable energy consumption across all Group sites, A 31% absolute reduction in Scope 3 emissions, including those related to the value chain, with no exclusion of any greenhouse gas categories. By 2040: Achievement of Net Zero, corresponding to a 90% absolute reduction in total Group emi
Fujirebio Acquires Plasma Services Group and Strengthens Its Position as Provider of Critical and High Quality Biological Raw Materials to the IVD and Life Science Industries23.6.2025 14:00:00 EEST | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter “Plasma Services Group”). The transaction value has not been disclosed. Founded in 2004, Plasma Services Group has specialized in the collection, screening and supply of high quality and rare biological materials required for R&D and manufacturing in the in vitro diagnostics (IVD) and life science industries. The company is particularly well positioned in the field of rare diseases. From its state-of-the-art FDA registered, ISO certified facility in Moorestown, NJ, USA, Plasma Services Group provides sera and other samples for materials of control reagents and calibrators for a wide range of diseases and offers sample collection services globally. For more information about Plasma Services Group please visit www.plasmaservicesgroup.com
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression23.6.2025 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint is the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the active treatment group and the placebo group at week 6. A single dose of COMP360 25 mg versus placebo demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.6 in change at the primary endpoint. The Company plans to discuss these preliminary COMP005 data with the U.S. Food and Drug Administration (FDA), which has not yet reviewed the data. The ongoing Phase 3 COMP005 trial is the fir
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom